NCT01714739 is a Phase 1, PHASE2 clinical trial of Lirilumab in CANCER,NOS, sponsored by Bristol-Myers Squibb.

Who is sponsoring NCT01714739?

NCT01714739 is sponsored by Bristol-Myers Squibb.

What drugs are being tested in NCT01714739?

Interventions in NCT01714739: Lirilumab, Nivolumab, Ipilimumab.

What condition does NCT01714739 study?

NCT01714739 studies CANCER,NOS.

Is NCT01714739 still recruiting?

NCT01714739 is currently completed. Last updated 2 February 2023.

Are results published for NCT01714739?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2023-02-02 · How we verify

NCT01714739

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors

Completed Phase 1, PHASE2 Results posted Last updated 2 February 2023

What this trial tests

Phase 1, PHASE2 trial testing Lirilumab in CANCER,NOS in 337 participants. Completed in 13 December 2019.

Timeline

7 October 2012

Primary endpoint
13 December 2019

13 December 2019

Quick facts

Lead sponsor	Bristol-Myers Squibb
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	337
Start date	7 October 2012
Primary completion	13 December 2019
Estimated completion	13 December 2019
Sites	30 locations across France, Italy, Canada, Switzerland, United States, Spain

Drugs / interventions tested

Lirilumab — full drug profile →
Nivolumab (nivolumab) — full drug profile →
Ipilimumab — full drug profile →

Conditions studied

CANCER,NOS — all drugs for CANCER,NOS →

Sponsor

Bristol-Myers Squibb — full company profile →

Who can join

18 and older, any sex, with CANCER,NOS. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Number of Participants With Adverse Events (AEs) - Parts 1, 2 and 5 Primary · From first dose to 150 days post last dose (up to an average of 51 weeks and a maximum of 2.5 years)

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment.

Group	Value	95% CI
Part 1/2 Liri 0.1 + Nivo 3	4
Part 1/2: Liri 0.3 + Nivo 3	16
Part 1/2: Liri 1 + Nivo 3	15
Part 1/2: Liri 3 + Nivo 3	284
Part 5: Liri 3 + Nivo 3 + Ipi 1	10

Number of Participants With Serious Adverse Events (SAEs) - Parts 1, 2 and 5 Primary · From first dose to 150 days post last dose (up to an average of 51 weeks and a maximum of 2.5 years)

A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.

Group	Value	95% CI
Part 1/2 Liri 0.1 + Nivo 3	1
Part 1/2: Liri 0.3 + Nivo 3	8
Part 1/2: Liri 1 + Nivo 3	9
Part 1/2: Liri 3 + Nivo 3	205
Part 5: Liri 3 + Nivo 3 + Ipi 1	7

Number of Participants With Adverse Events (AEs) Leading to Discontinuation - Parts 1, 2 and 5 Primary · From first dose to 150 days post last dose (up to an average of 51 weeks and a maximum of 2.5 years)

Number of participants that experienced an AE leading to discontinuation. An AE is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment.

Group	Value	95% CI
Part 1/2 Liri 0.1 + Nivo 3	1
Part 1/2: Liri 0.3 + Nivo 3	1
Part 1/2: Liri 1 + Nivo 3	4
Part 1/2: Liri 3 + Nivo 3	49
Part 5: Liri 3 + Nivo 3 + Ipi 1	5

The Number of Participant Deaths in the Study - Parts 1, 2 and 5 Primary · From first dose to 150 days post last dose (up to an average of 51 weeks and a maximum of 2.5 years)

The number of participants who died.

Group	Value	95% CI
Part 1/2 Liri 0.1 + Nivo 3	2
Part 1/2: Liri 0.3 + Nivo 3	7
Part 1/2: Liri 1 + Nivo 3	5
Part 1/2: Liri 3 + Nivo 3	219
Part 5: Liri 3 + Nivo 3 + Ipi 1	5

Number of Participants With Clinical Laboratory Test Abnormalities - Parts 1, 2 and 5 Primary · From first dose to 150 days post last dose (up to an average of 51 weeks and a maximum of 2.5 years)

Number of participants that experienced a clinical laboratory test abnormality, including hematology and serum chemistry, and thyroid panel abnormalities. Abnormalities considered are those Grade 3-4 events with a \>= 1 grade increase from baseline. Laboratory tests are graded using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 where Grade 3 is severe, and Grade 4 is life threatening. Baseline is defined as the last non-missing measurement prior to the first dosing date and time.

Absolute Neutrophil Count - Grade 3

Group	Value	95% CI
Part 1/2 Liri 0.1 + Nivo 3	0
Part 1/2: Liri 0.3 + Nivo 3	0
Part 1/2: Liri 1 + Nivo 3	0
Part 1/2: Liri 3 + Nivo 3	2
Part 5: Liri 3 + Nivo 3 + Ipi 1	0

Absolute Neutrophil Count - Grade 4

Group	Value	95% CI
Part 1/2 Liri 0.1 + Nivo 3	0
Part 1/2: Liri 0.3 + Nivo 3	1
Part 1/2: Liri 1 + Nivo 3	0
Part 1/2: Liri 3 + Nivo 3	0
Part 5: Liri 3 + Nivo 3 + Ipi 1	0

Alanine Amino Transferase (ALT) - Grade 3

Group	Value	95% CI
Part 1/2 Liri 0.1 + Nivo 3	0
Part 1/2: Liri 0.3 + Nivo 3	0
Part 1/2: Liri 1 + Nivo 3	1
Part 1/2: Liri 3 + Nivo 3	0
Part 5: Liri 3 + Nivo 3 + Ipi 1	0

Alanine Amino Transferase (ALT) - Grade 4

Group	Value	95% CI
Part 1/2 Liri 0.1 + Nivo 3	0
Part 1/2: Liri 0.3 + Nivo 3	0
Part 1/2: Liri 1 + Nivo 3	0
Part 1/2: Liri 3 + Nivo 3	0
Part 5: Liri 3 + Nivo 3 + Ipi 1	0

Albumin - Grade 3

Group	Value	95% CI
Part 1/2 Liri 0.1 + Nivo 3	0
Part 1/2: Liri 0.3 + Nivo 3	0
Part 1/2: Liri 1 + Nivo 3	0
Part 1/2: Liri 3 + Nivo 3	1
Part 5: Liri 3 + Nivo 3 + Ipi 1	0

Albumin - Grade 4

Group	Value	95% CI
Part 1/2 Liri 0.1 + Nivo 3	0
Part 1/2: Liri 0.3 + Nivo 3	0
Part 1/2: Liri 1 + Nivo 3	0
Part 1/2: Liri 3 + Nivo 3	0
Part 5: Liri 3 + Nivo 3 + Ipi 1	0

Alkaline Phosphatase (ALP) - Grade 3

Group	Value	95% CI
Part 1/2 Liri 0.1 + Nivo 3	0
Part 1/2: Liri 0.3 + Nivo 3	1
Part 1/2: Liri 1 + Nivo 3	0
Part 1/2: Liri 3 + Nivo 3	6
Part 5: Liri 3 + Nivo 3 + Ipi 1	0

Alkaline Phosphatase (ALP) - Grade 4

Group	Value	95% CI
Part 1/2 Liri 0.1 + Nivo 3	0
Part 1/2: Liri 0.3 + Nivo 3	0
Part 1/2: Liri 1 + Nivo 3	0
Part 1/2: Liri 3 + Nivo 3	0
Part 5: Liri 3 + Nivo 3 + Ipi 1	0

Objective Response Rate (ORR) Primary · From first dose up to approximately 2.5 years

Objective Response Rate (ORR) is defined as the percent of participants whose best overall response (BOR) is either a complete response (CR) or partial response (PR). BOR for a participant was derived using investigator-provided tumor measurements per RECIST v1.1. CR is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Group	Value	95% CI
Part 1/2 Liri 0.1 + Nivo 3	25.0	0.6 – 80.6
Part 1/2: Liri 0.3 + Nivo 3	37.5	15.2 – 64.6
Part 1/2: Liri 1 + Nivo 3	40.0	16.3 – 67.7
Part 1/2: Liri 3 + Nivo 3	14.6	10.8 – 19.3
Part 3: PBO + Nivo 240	50.0	1.3 – 98.7
Part 3: Liri 240 + Nivo 240	0	0.0 – 70.8
Part 5: Liri 3 + Nivo 3 + Ipi 1	0	0.0 – 30.8

Disease Control Rate (DCR) - Part 3 Secondary · From first dose up to approximately 2.5 years

Disease Control Rate (DCR) is defined as the percentage of participants with a best overall response (BOR) of complete response (CR), partial response (PR), or stable disease (SD). CR is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease

Group	Value	95% CI
Part 3: PBO + Nivo 240	50.0	1.3 – 98.7
Part 3: Liri 240 + Nivo 240	33.3	0.8 – 90.6

Median Duration of Response (mDOR) - Parts 3 and 5 Secondary · From first dose to the date of the first documented tumor progression as determined or death due to any cause, whichever occurs first. (Up to approximately 2.5 years)

DOR is defined as the time from the date of first response (CR or PR) to the date of first objectively documented tumor progression as determined using RECIST v1.1 or death due to any cause, whichever occurs first. Participant who remain alive and have not progressed were censored on the date of their last evaluable tumor assessment. Participants who started subsequent anticancer therapy without a prior reported progression were censored at the last evaluable tumor assessment prior to initiation of the subsequent anticancer therapy. CR is defined as the disappearance of all target lesions. Any

Group	Value	95% CI
Part 3: PBO + Nivo 240	NA	40.0 – 40.0

Median Time to Response (mTTR) - Part 3 Secondary · From date of first dose of study medication to the date of the first documented objective response (up to approximately 2.5 years)

TTR is defined as the time from the first dosing date to the date of the first documented objective response (CR or PR). CR is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Group	Value	95% CI
Part 3: PBO + Nivo 240	8.10	8.1 – 8.1

The Number of Participants With >=50% or >=80% Tumor Reduction - Parts 3 and 5 Secondary · From first dose until progressive disease (PD) or treatment discontinuation, whichever occurs earlier. (Up to approximately 2.5 years)

Depth of response is defined as the target tumor burden percent change from baseline at nadir for each participant as measured by the number of participants with \>= 50% and \>= 80% tumor reduction. Tumor assessments are performed every 8 weeks from first dose date for 48 weeks, and then every 12 weeks thereafter until progressive disease (PD) or treatment discontinuation, whichever occurs earlier.

WITH >=50% TUMOR REDUCTION

Group	Value	95% CI
Part 3: PBO + Nivo 240	1
Part 3: Liri 240 + Nivo 240	2
Part 5: Liri 3 + Nivo 3 + Ipi 1	0

WITH >=80% TUMOR REDUCTION

Group	Value	95% CI
Part 3: PBO + Nivo 240	0
Part 3: Liri 240 + Nivo 240	1
Part 5: Liri 3 + Nivo 3 + Ipi 1	0

Overall Survival (OS) - Part 3 Secondary · From date of first dose of study medication to the date of death for any cause. (Up to approximately 2.5 years)

Overall Survival (OS) is defined as the time from date of first dose of study medication to the date of death for any cause. A participant who has not died will be censored at last known date alive. OS for a participant who initiated new cancer treatment, will also be censored at the date of the new treatment initiation. Estimated by Kaplan-Meier Method.

Group	Value	95% CI
Part 3: PBO + Nivo 240	NA	0.2 – 1.2
Part 3: Liri 240 + Nivo 240	0.3	0.1 – 0.8

Progression Free Survival (PFS) - Part 3 Secondary · From first dose to the date of first objectively documented disease progression or death due to any cause, whichever occurs first. (Up to approximately 2.5 years)

PFS is defined as the time from the first dosing date to the date of first objectively documented disease progression or death due to any cause, whichever occurs first. Participants who died without a reported prior progression was considered to have progressed on the date of their death. Participants alive with no progression were censored on the last evaluable tumor assessment date. Participants who started subsequent therapy with no prior progression were censored at the last evaluable tumor assessment prior to initiation of the subsequent therapy. Participants with no post-baseline tumor a

Group	Value	95% CI
Part 3: PBO + Nivo 240	NA	1.1 – 11.0
Part 3: Liri 240 + Nivo 240	1.6	1.1 – 7.4

Adverse events — posted to ClinicalTrials.gov

Time frame: Participants were assessed for All-Cause Mortality from their first dose until the study was completed (up to approximately 2.5 years). SAEs and Other AEs were assessed from first dose to 150 days post last dose (up to an average of 51 weeks and a maximum of 2.5 years).. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Part 1/2 Liri 0.1 + Nivo 3

Serious: 1/4 (25%)

Deaths: 2/4

Part 1/2: Liri 0.3 + Nivo 3

Serious: 8/16 (50%)

Deaths: 7/16

Part 1/2: Liri 1 + Nivo 3

Serious: 9/15 (60%)

Deaths: 5/15

Part 1/2: Liri 3 + Nivo 3

Serious: 205/287 (71%)

Deaths: 219/287

Part 3: PBO + Nivo 240

Serious: 2/2 (100%)

Deaths: 1/2

Part 3: Liri 240 + Nivo 240

Serious: 3/3 (100%)

Deaths: 3/3

Part 5: Liri 3 + Nivo 3 + Ipi 1

Serious: 7/10 (70%)

Deaths: 5/10

Serious adverse events (190 terms)

Reaction	System	Part 1/2 Liri 0.1 + Nivo 3	Part 1/2: Liri 0.3 + Nivo 3	Part 1/2: Liri 1 + Nivo 3	Part 1/2: Liri 3 + Nivo 3	Part 3: PBO + Nivo 240	Part 3: Liri 240 + Nivo 240	Part 5: Liri 3 + Nivo 3 + …
Malignant neoplasm progression	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—	—	—	—	—	—
Dyspnoea	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—
Pyrexia	General disorders	—	—	—	—	—	—	—
Anaemia	Blood and lymphatic system disorders	—	—	—	—	—	—	—
Pneumonia	Infections and infestations	—	—	—	—	—	—	—
Sepsis	Infections and infestations	—	—	—	—	—	—	—
Infusion related reaction	Injury, poisoning and procedural complications	—	—	—	—	—	—	—
General physical health deterioration	General disorders	—	—	—	—	—	—	—
Hypercalcaemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—
Dysphagia	Gastrointestinal disorders	—	—	—	—	—	—	—
Colitis	Gastrointestinal disorders	—	—	—	—	—	—	—
Haemoptysis	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—
Lung disorder	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—
Pneumonia aspiration	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—	—	—	—	—
Face oedema	General disorders	—	—	—	—	—	—	—
Dehydration	Metabolism and nutrition disorders	—	—	—	—	—	—	—
Pneumonitis	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—
Respiratory distress	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—
Respiratory failure	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—
Small intestinal obstruction	Gastrointestinal disorders	—	—	—	—	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—	—	—	—	—
Hypokalaemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—
Tumour haemorrhage	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—	—	—	—	—	—
Hypoxia	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—

Other adverse events (278 terms — click to expand)

Reaction	System	Part 1/2 Liri 0.1 + Nivo 3	Part 1/2: Liri 0.3 + Nivo 3	Part 1/2: Liri 1 + Nivo 3	Part 1/2: Liri 3 + Nivo 3	Part 3: PBO + Nivo 240	Part 3: Liri 240 + Nivo 240	Part 5: Liri 3 + Nivo 3 + …
Fatigue	General disorders	—	—	—	—	—	—	—
Anaemia	Blood and lymphatic system disorders	—	—	—	—	—	—	—
Pyrexia	General disorders	—	—	—	—	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—	—	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—
Constipation	Gastrointestinal disorders	—	—	—	—	—	—	—
Decreased appetite	Metabolism and nutrition disorders	—	—	—	—	—	—	—
Pruritus	Skin and subcutaneous tissue disorders	—	—	—	—	—	—	—
Dyspnoea	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—
Headache	Nervous system disorders	—	—	—	—	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—	—	—	—	—
Asthenia	General disorders	—	—	—	—	—	—	—
Rash	Skin and subcutaneous tissue disorders	—	—	—	—	—	—	—
Weight decreased	Investigations	—	—	—	—	—	—	—
Arthralgia	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—
Back pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—
Chills	General disorders	—	—	—	—	—	—	—
Dysphagia	Gastrointestinal disorders	—	—	—	—	—	—	—
Oedema peripheral	General disorders	—	—	—	—	—	—	—
Hyponatraemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—
Hypomagnesaemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—
Neck pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—
Hypothyroidism	Endocrine disorders	—	—	—	—	—	—	—
Abdominal pain	Gastrointestinal disorders	—	—	—	—	—	—	—
Infusion related reaction	Injury, poisoning and procedural complications	—	—	—	—	—	—	—
Hypokalaemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—
Dizziness	Nervous system disorders	—	—	—	—	—	—	—
Aspartate aminotransferase increased	Investigations	—	—	—	—	—	—	—
Lipase increased	Investigations	—	—	—	—	—	—	—
Hypercalcaemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—
Dry mouth	Gastrointestinal disorders	—	—	—	—	—	—	—
Amylase increased	Investigations	—	—	—	—	—	—	—
Anxiety	Psychiatric disorders	—	—	—	—	—	—	—
Hypotension	Vascular disorders	—	—	—	—	—	—	—
Upper respiratory tract infection	Infections and infestations	—	—	—	—	—	—	—
Dysphonia	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—
Mucosal inflammation	General disorders	—	—	—	—	—	—	—
Blood creatinine increased	Investigations	—	—	—	—	—	—	—
Dehydration	Metabolism and nutrition disorders	—	—	—	—	—	—	—

Most-reported serious reactions: Malignant neoplasm progression, Dyspnoea, Pyrexia, Anaemia, Pneumonia, Sepsis, Infusion related reaction, General physical health deterioration.

Data from ClinicalTrials.gov NCT01714739 adverse events section.

Sponsor's own description

To assess the safety and tolerability and preliminary anti-tumor activity of lirilumab (BMS-986015) given in combination with nivolumab (BMS-936558) and to identify dose limiting toxicities (DLTs) and the maximally tolerated dose (MTD) of the combination. In addition, to assess the combinations of lirilumab and nivolumab or lirilumab and nivolumab plus ipilimumab (BMS-734016) in subjects with advanced (metastatic and/or unresectable) refractory solid tumors.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Immune checkpoint blockade: a common denominator approach to cancer therapy.
Topalian SL, Drake CG, Pardoll DM. · · 2015 · cited 3276× · PMID 25858804 · DOI 10.1016/j.ccell.2015.03.001
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
Topalian SL, Sznol M, McDermott DF, Kluger HM, et al · · 2014 · cited 1751× · PMID 24590637 · DOI 10.1200/jco.2013.53.0105
Exploring the NK cell platform for cancer immunotherapy.
Myers JA, Miller JS. · · 2021 · cited 977× · PMID 32934330 · DOI 10.1038/s41571-020-0426-7
Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma.
Auslander N, Zhang G, Lee JS, Frederick DT, et al · · 2018 · cited 586× · PMID 30127394 · DOI 10.1038/s41591-018-0157-9
Next generation of immune checkpoint therapy in cancer: new developments and challenges.
Marin-Acevedo JA, Dholaria B, Soyano AE, Knutson KL, et al · · 2018 · cited 582× · PMID 29544515 · DOI 10.1186/s13045-018-0582-8
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).
Cohen EEW, Bell RB, Bifulco CB, Burtness B, et al · · 2019 · cited 528× · PMID 31307547 · DOI 10.1186/s40425-019-0662-5
Immunology and Immunotherapy of Head and Neck Cancer.
Ferris RL. · · 2015 · cited 515× · PMID 26351330 · DOI 10.1200/jco.2015.61.1509
Cancer immunotherapies targeting the PD-1 signaling pathway.
Iwai Y, Hamanishi J, Chamoto K, Honjo T. · · 2017 · cited 478× · PMID 28376884 · DOI 10.1186/s12929-017-0329-9

Verify or expand the search:

Other trials of Lirilumab

Trials testing the same drug.

NCT03347123 — A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Ma · Phase 1, PHASE2 · terminated
NCT03341936 — Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN · Phase 2 · active not recruiting
NCT03203876 — A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced an · Phase 1 · completed
NCT02599649 — Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS) · Phase 2 · terminated
NCT02481297 — Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients · Phase 2 · completed

Other Bristol-Myers Squibb trials

Trials by the same sponsor.

NCT07441408 — Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis · Phase 3 · not yet recruiting
NCT07459543 — A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unre · Phase 4 · not yet recruiting
NCT07285798 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder · Phase 3 · not yet recruiting
NCT07284745 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism · Phase 3 · not yet recruiting
NCT07492680 — A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic S · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01714739 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bristol-Myers Squibb
Last refreshed: 2 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01714739.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing